Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden heart risk: routine cancer scans could reveal cardiovascular danger in breast cancer survivors

NCT ID NCT07703033

Knowledge-focused Sponsor: UMC Utrecht Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests whether measuring calcium buildup in heart arteries from routine radiotherapy planning CT scans can identify breast cancer patients at risk for heart disease. Researchers will share this personalized risk information with patients and their doctors to see if it influences treatment decisions and patient satisfaction. The goal is to improve long-term heart health in breast cancer survivors without extra scans or radiation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
measuring coronary artery calcifications (Agatston score) using routine radiotherapy planning CT scans and communicating the associated risk of cardiovascular disease to the patient
What this could lead to
If successful, this approach could help identify breast cancer patients at high risk for heart disease earlier, leading to better preventive care and improved long-term health.
What could go wrong
This is a decision-impact study, not a treatment trial. It measures whether sharing risk information changes care, but it may not directly improve health outcomes. Some patients may experience anxiety from learning their heart risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosed with breast cancer or ductal carcinoma in situ * Planned for radiotherapy * From 35 years of age onwards Exclusion Criteria: * Pregnancy * Breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm ductal breast carcinoma in situ

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Cardiovascular (CV) risk Coronary artery calcifications

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam University Medical Center

    NOT_YET_RECRUITING

    Amsterdam, Netherlands

  • Champalimaud Foundation

    NOT_YET_RECRUITING

    Lisbon, Portugal

  • LMU University Hospital

    NOT_YET_RECRUITING

    München, Germany

  • RegionH

    NOT_YET_RECRUITING

    Copenhagen, Denmark

  • St. Antonius Hospital

    RECRUITING

    Utrecht, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.